Trifluoperazine, sold for decades as Stelazine, is one of the older high-potency phenothiazines. It was approved by the FDA in 1959, used heavily through the 1970s and 1980s, and gradually displaced by second-generation drugs. It is still on the WHO Model List of Essential Medicines and remains in active use in many parts of the world. For some patients, particularly those who don't tolerate the metabolic effects of newer drugs, it remains a reasonable option — provided its movement-heavy side effect profile is managed carefully.
Trifluoperazine is a high-potency first-generation antipsychotic with substantial EPS and akathisia risk but comparatively mild weight gain and metabolic effects.
How its profile is shaped
Trifluoperazine binds tightly to dopamine D2 receptors and has relatively little antihistaminic, anticholinergic, or alpha-adrenergic activity. That receptor profile gives it a side effect signature that resembles haloperidol and fluphenazine more than chlorpromazine: heavier on movement effects, lighter on sedation and metabolism. Some clinicians describe it as feeling closer to a high-potency typical than its phenothiazine chemistry might suggest.
The two main dose ranges
Trifluoperazine is one of a handful of antipsychotics with FDA approval for non-psychotic anxiety as well as schizophrenia, although the anxiety indication is rarely used today. The dose range matters because side effects scale with dose:
- Anxiety doses (historically 1–2 mg twice daily) — generally lighter side effect burden but a use case that has been largely superseded by safer agents.
- Schizophrenia doses (commonly 5–40 mg/day in divided doses) — full antipsychotic effect with proportionally higher EPS, akathisia, and tardive dyskinesia risk.
Movement side effects
Acute dystonia
Sudden, painful muscle contractions of the neck, face, or eyes — most likely in the first few days of treatment, particularly in younger men. Treated with intramuscular benztropine or diphenhydramine.
Drug-induced parkinsonism
Tremor, stiffness, slowed movement, and a mask-like facial expression. Usually develops over days to weeks. Lowering the dose or adding an anticholinergic such as benztropine often helps. See our EPS overview.
Akathisia
An inner restlessness — pacing, foot-tapping, an inability to sit still — that many patients describe as the most distressing antipsychotic side effect. Strategies include dose reduction, propranolol, mirtazapine, or low-dose benzodiazepines. See our akathisia guide.
Tardive dyskinesia
Long-term involuntary movements of the face, tongue, fingers, or trunk. Risk rises with cumulative exposure and is higher in older adults and women. Annual AIMS examinations are standard. See our TD article.
Sedation and cognition
Sedation with trifluoperazine is generally mild compared with low-potency phenothiazines or olanzapine. Some patients describe a flattened or dysphoric feeling, which can sometimes be confused with negative symptoms. Cognitive slowing is possible at higher doses.
Metabolic profile
Weight gain on trifluoperazine is usually modest — typically less than with olanzapine, quetiapine, or clozapine. Diabetes risk is lower than with the most metabolically heavy second-generation agents. For patients with strong metabolic concerns, this is part of why high-potency first-generation drugs remain on the table.
Anticholinergic effects
Dry mouth, blurred vision, constipation, and urinary hesitancy occur but are generally milder than with chlorpromazine or thioridazine. Adding an anticholinergic for EPS can intensify all of these.
Hyperprolactinemia
D2 blockade in the pituitary stalk lifts prolactin substantially. Symptoms include menstrual irregularity, galactorrhoea, sexual dysfunction, and over the long term, possible bone density loss. Baseline and follow-up prolactin checks are reasonable. See hyperprolactinemia article.
Cardiovascular effects
Trifluoperazine can cause modest QTc prolongation, generally less than thioridazine or droperidol. Orthostatic hypotension is uncommon at typical doses. See QT prolongation article.
Less common but important effects
- Neuroleptic malignant syndrome — rare and life-threatening
- Photosensitivity and skin reactions — phenothiazines as a class can cause sun-sensitive rash; sunscreen and protective clothing help
- Hepatic effects — uncommon liver enzyme elevations
- Lowered seizure threshold — modest, similar to other antipsychotics
- Blood dyscrasias — rare
High fever, severe muscle rigidity, confusion, or autonomic instability appear together — possible NMS. Sustained involuntary face or tongue movements deserve urgent evaluation.
Who might do well on it
- People with strong metabolic concerns about second-generation drugs
- People who responded to it historically
- People in settings where cost or availability favour older drugs
- People who tolerate the receptor profile
Who might not
- People with prior severe EPS
- Older adults at high TD risk
- People with cardiac arrhythmias or QT-prolonging comorbidities
- People very sensitive to prolactin elevation
The big picture
Trifluoperazine is an effective, well-studied antipsychotic with a side effect profile that asks a lot from patients in the movement domain but spares them in the metabolic domain. Whether that trade-off is right depends on a careful conversation with your prescriber about your priorities, your medical history, and what alternatives are realistically available. Many people have done well on trifluoperazine for years; others find it intolerable. There is no universal answer.
This article is for educational purposes only and is not medical advice. Information is summarised from publicly available FDA labelling and peer-reviewed literature. Always consult your prescribing clinician before starting, stopping, or changing any medication.